Sleep devices company ResMed has told investors it can deliver high single-digit revenue growth over the next five years, as it launches new products designed to treat insomnia and seeks to convince the market of its resilience to the Ozempic phenomenon.

ResMed has dismissed concerns that the rising popularity of weight-loss drugs will reduce obesity and undercut demand for the company’s key product.